At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMRX Immuneering Corp
Post-Mkt 04-29 18:20:44 EDT
5.25
+0.02
+0.38%
盘后5.36
+0.11+2.08%
17:38 EDT
High5.34Low5.16Vol563.69K
Open5.25D1 Closing5.23Amplitude3.44%
Mkt Cap338.99MTradable Cap285.66MTotal Shares64.57M
T/O2.95MT/O Rate1.04%Tradable Shares54.41M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Immuneering announces updated data from Phase 2a trial for atebimetinib
TIPRANKS  ·  04-22
Immuneering announces updated data from Phase 2a trial for atebimetinib
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
GlobeNewswire  ·  04-22
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and McKesson (MCK)
TIPRANKS  ·  04-21
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and McKesson (MCK)
Immuneering announces annual shareholder meeting webcast
Reuters  ·  04-21
Immuneering announces annual shareholder meeting webcast
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
GlobeNewswire  ·  04-20
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Immuneering (IMRX) and Maze Therapeutics, Inc. (MAZE)
TIPRANKS  ·  04-14
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Immuneering (IMRX) and Maze Therapeutics, Inc. (MAZE)
Immuneering CEO to join Needham Virtual Healthcare Conference fireside chat
Reuters  ·  04-07
Immuneering CEO to join Needham Virtual Healthcare Conference fireside chat
Immuneering to present atebimetinib ctDNA analysis at AACR Annual Meeting
Reuters  ·  03-18
Immuneering to present atebimetinib ctDNA analysis at AACR Annual Meeting
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
GlobeNewswire  ·  03-18
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
Mizuho Securities Sticks to Their Buy Rating for Immuneering (IMRX)
TIPRANKS  ·  03-12
Mizuho Securities Sticks to Their Buy Rating for Immuneering (IMRX)
Immuneering price target lowered to $12 from $13 at Piper Sandler
TIPRANKS  ·  03-09
Immuneering price target lowered to $12 from $13 at Piper Sandler
Immuneering Price Target Maintained With a $11.00/Share by Needham
Dow Jones  ·  03-09
Immuneering Price Target Maintained With a $11.00/Share by Needham
BUZZ-U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
Reuters  ·  03-07
BUZZ-U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
BUZZ-U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
Reuters  ·  03-06
BUZZ-U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
BUZZ-U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences
Reuters  ·  03-06
BUZZ-U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences
Shares of Immuneering Down 1.8% Premarket After Q4 Results
THOMSON REUTERS  ·  03-06
Shares of Immuneering Down 1.8% Premarket After Q4 Results
BUZZ-Immuneering rises as quarterly loss comes in below estimates
Reuters  ·  03-06
BUZZ-Immuneering rises as quarterly loss comes in below estimates
Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs
Reuters  ·  03-06
Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs
Immuneering reports Q4 EPS (18), consensus (31c)
TIPRANKS  ·  03-06
Immuneering reports Q4 EPS (18), consensus (31c)
Immuneering sees cash runway into 2029
TIPRANKS  ·  03-06
Immuneering sees cash runway into 2029

Introduction

Company Name.
Immuneering Corp
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Issue price:
--